A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Miguel ESCOBAR, MD
The University of Texas Health Science Center, Houston
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Queen Elisabeth - Kota Kinabalu
Kota Kinabalu, Sabah Province, Malaysia
- Hospital Ampang
Ampang, Selangor Province, Malaysia
- Hospital Universitario Dr. José Eleuterio González de Nuevo León
Monterrey, Nuevo León, Mexico
- Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, South Africa
- Chiang Mai University
Chiang Mai, Thailand
- Maharaj Nakorn Chiangmai Hospital, Chiangmai University
Chiang Mai, Thailand
- Acibadem Adana Hospital
Seyhan, Adana, Turkey (Türkiye)
- Hacettepe Üniversitesi Rektörlüğü Sihhiye
Altındağ, Ankara, Turkey (Türkiye)
- Istanbul Üniversitesi Onkoloji Enstitusu
Fatih, Istanbul, Turkey (Türkiye)
- Karadeniz Teknik Üniversitesi
Trabzon, Trabzon, Turkey (Türkiye)
- Orthopaedic Institute for Children - Orthopaedic Hemophilia Treatment Center
Los Angeles, California, United States
- Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
- Tulane Univertsity School of Medecine
New Orleans, Louisiana, United States
- M Health Fairview Center for Bleeding and Clotting Disorders
Minneapolis, Minnesota, United States
- University of Texas Health Science Center at Houston
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Jun 2024
- Primary completion
- 1 Jun 2025
- Completion
- 1 Jun 2025
- Last update posted
- 9 Jul 2025
- Registered enrollment
- 2
- Registry id
- NCT05695391
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.